Novo Nordisk A/S (NVO)
46.94
+0.20
(+0.44%)
USD |
NYSE |
Aug 24, 16:00
47.05
+0.10
(+0.22%)
After-Hours: 20:00
Novo Nordisk Net Income (Quarterly) : 3.265B for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.265B |
| March 31, 2026 | 7.604B |
| December 31, 2025 | 4.191B |
| September 30, 2025 | 3.133B |
| June 30, 2025 | 4.026B |
| March 31, 2025 | 4.096B |
| December 31, 2024 | 4.037B |
| September 30, 2024 | 4.020B |
| June 30, 2024 | 2.894B |
| March 31, 2024 | 3.698B |
| December 31, 2023 | 3.167B |
| September 30, 2023 | 3.281B |
| June 30, 2023 | 2.838B |
| March 31, 2023 | 2.856B |
| December 31, 2022 | 1.864B |
| September 30, 2022 | 1.949B |
| June 30, 2022 | 1.905B |
| March 31, 2022 | 2.142B |
| December 31, 2021 | 1.674B |
| September 30, 2021 | 1.921B |
| June 30, 2021 | 1.965B |
| March 31, 2021 | 2.044B |
| December 31, 2020 | 1.492B |
| September 30, 2020 | 1.617B |
| June 30, 2020 | 1.569B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.754B |
| December 31, 2019 | 1.292B |
| September 30, 2019 | 1.519B |
| June 30, 2019 | 1.444B |
| March 31, 2019 | 1.589B |
| December 31, 2018 | 1.299B |
| September 30, 2018 | 1.410B |
| June 30, 2018 | 1.654B |
| March 31, 2018 | 1.774B |
| December 31, 2017 | 1.306B |
| September 30, 2017 | 1.543B |
| June 30, 2017 | 1.473B |
| March 31, 2017 | 1.456B |
| December 31, 2016 | 1.260B |
| September 30, 2016 | 1.470B |
| June 30, 2016 | 1.513B |
| March 31, 2016 | 1.397B |
| December 31, 2015 | 1.212B |
| September 30, 2015 | 1.249B |
| June 30, 2015 | 1.237B |
| March 31, 2015 | 1.490B |
| December 31, 2014 | 1.096B |
| September 30, 2014 | 1.156B |
| June 30, 2014 | 1.285B |
| March 31, 2014 | 1.186B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 3.076B |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
| Merck & Co., Inc. | -1.337B |
| Novartis AG | 3.259B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 12.21B |
| Total Expenses (Quarterly) | 8.946B |
| EPS Diluted (Quarterly) | 0.7362 |
| Enterprise Value | 170.94B |
| Gross Profit Margin (Quarterly) | 78.21% |
| Profit Margin (Quarterly) | 26.74% |
| Earnings Yield | 8.72% |
| Operating Earnings Yield | 11.19% |
| Normalized Earnings Yield | 9.068 |